Explore the words cloud of the DocTIS project. It provides you a very rough idea of what is the project "DocTIS" about.
The following table provides information about the project.
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
|Coordinator Country||Spain [ES]|
|Total cost||6˙260˙050 €|
|EC max contribution||6˙260˙050 € (100%)|
1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
|Duration (year-month-day)||from 2020-01-01 to 2025-03-31|
Take a look of project's partnership.
|1||FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA||ES (BARCELONA)||coordinator||1˙122˙820.00|
|2||FUNDACIO CENTRE DE REGULACIO GENOMICA||ES (BARCELONA)||participant||1˙065˙750.00|
|3||LINKOPINGS UNIVERSITET||SE (LINKOPING)||participant||920˙045.00|
|4||CARDIFF UNIVERSITY||UK (CARDIFF)||participant||890˙412.00|
|5||CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER||ES (BARCELONA)||participant||575˙000.00|
|6||HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY||US (HUNTSVILLE)||participant||567˙317.00|
|7||IMIDOMICS SL||ES (BARCELONA)||participant||366˙655.00|
|8||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||participant||251˙250.00|
|9||UNIVERSITA DEGLI STUDI DI VERONA||IT (VERONA)||participant||251˙231.00|
|10||ZABALA INNOVATION CONSULTING, S.A.||ES (MUTILVA ALTA NAVARRA)||participant||249˙568.00|
Immune-Mediated Inflammatory Diseases (IMIDs) are a group of common autoimmune diseases that include clinically heterogeneous disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus. Despite their clinical heterogeneity, IMIDs share a significant number of features at the molecular and cellular levels. Recently developed therapies targeting common key molecules of the immune system like anti-TNF agents, have collectively resulted in a significant improvement in the management of IMIDs. Still, the complete control of the chronic inflammatory process is rarely attained, and too many patients experience a poor response, if at all. This inefficacy has become a major economic burden and severely impacts on the wellbeing of many European citizens. The DocTIS projects aims to profoundly change this trend by identifying highly effective combinatorial therapies as well as the group of patients where this response will be optimal. Using the standardized samples from one of the world’s largest biobanks specialized in IMIDs, new molecular data will be generated using advanced high-throughput technologies including single cell RNA-seq. Systems biology methods will be applied to this unique clinical and molecular data to model the response to targeted therapies and predict what drug combinations will act synergistically and on which types of patients. After validation in a preclinical stage, the optimal combinatorial therapy will be tested in a group of patients with a positive biomarker profile. Using a basket trial, a new type of clinical trial design that incorporates molecular marker information, the DocTIS project will provide proof of concept of the utility of combinatorial therapy and personalized medicine for the effective control of disease activity in IMIDs.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DOCTIS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DOCTIS" are provided by the European Opendata Portal: CORDIS opendata.
Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel Assessment strategiesRead More
Unification of treatments and Interventions for Tinnitus patientsRead More
Accurate, Rapid, Robust and Economical diagnostic technoliogieS for TuberculosisRead More